AbbVie Inc (ABBV)vsAdagio Medical Holdings, Inc Common Stock (ADGM)
ABBV
AbbVie Inc
$291.31
+1.07%
HEALTHCARE · Cap: $521.11B
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.06
+6.39%
HEALTHCARE · Cap: $2.28M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 48185301% more annual revenue ($66.01B vs $137,000). ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
ADGM
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$291.31
$134.02 premium
Intrinsic value data unavailable for ADGM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 75.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Debt/Equity. Revenue growth of 75.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while ADGM is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.23 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 33/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?